| Previous Close | 6.150 |
| Open | 6.240 |
| Bid | 6.280 x 1400 |
| Ask | 6.290 x 1700 |
| Day's Range | 6.170 - 6.340 |
| 52 Week Range | 5.280 - 9.860 |
| Volume | 941,482 |
| Avg. Volume | 1,537,063 |
| Market Cap | 567.53M |
| Beta | 1.48 |
| PE Ratio (TTM) | -5.86 |
| EPS (TTM) | -1.07 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.83 |
- ACCESSWIRE•3 days ago
Today's Research Reports on Trending Tickers: Exact Sciences and Inovio Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / September 22, 2017 / U.S. markets retreated from record highs a day after the Federal Reserve announced that it would begin unwinding its $4.5 trillion balance sheet in October ...
- MarketWatch•4 days ago
Inovio shares jump 5% premarket after two peer-reviewed paper support its research
Inovio Pharmaceuticals Inc. shares climbed about 5% in premarket trade Thursday, after the company said its DNA-based monoclonal antibody program (dMAb) has been boosted by two peer-reviewed scientific ...
- GlobeNewswire•4 days ago
Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies
PLYMOUTH MEETING, Pa., Sept. 21, 2017-- Inovio Pharmaceuticals, Inc. today announced that the development of its DNA-based monoclonal antibody program received a boost from two peer-reviewed scientific ...
